Antibody-drug conjugate news and latest updates

Home Antibody-drug conjugates

Latest Posts

News and Trends 20 Nov 2023

M&As: what’s up with the ADC buying spree?

Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC…

November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter

In Depth 13 Oct 2023

How close are we to a cure for metastatic breast cancer?

Currently considered an incurable disease, there is a lot of work being done around developing better treatment options for metastatic breast cancer, and, ultimately, a cure. Numerous promising candidates are…

October 13, 2023 - 8 minutesmins - By Willow Shah-Neville

News and Trends 27 Jul 2023

Epsilogen completes first clinical trial of IgE antibody to treat cancer

Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The…

July 27, 2023 - 2 minutesmins - By Jim Cornall

In Depth 26 Jul 2023

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine

The first-ever antibody-drug conjugate (ADC) to be approved, gemtuzumab ozogamicin, raised hope for a new class of drugs to treat cancer. But the drug was then withdrawn following a black…

July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter

Podcast 7 Jul 2023

Beyond Biotech podcast 53: Antibody-drug conjugates

On the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink…

July 7, 2023 - 1 minutemin - By Jim Cornall

News and Trends 1 Jun 2023

Lonza boosts ADC portfolio with Synaffix acquisition

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs). While ADCs offer widespread and targeted treatment…

June 1, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

ADC firm Adcentrx Therapeutics aims for clinic after $38M boost

Antibody-drug conjugate (ADC) biotech company Adcentrx Therapeutics has closed a $38 million Series A+ financing. The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta…

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Apr 2023

FDA approves Genentech’s lymphoma drug

Genentech, a member of the Roche Group, has announced the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone…

April 20, 2023 - 4 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 14 Apr 2023

TORL BioTherapeutics launches with $158M to target cancer

TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a $158 million Series B financing. TORL's…

April 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets…

April 4, 2023 - 3 minutesmins - By Jim Cornall

Podcast 31 Mar 2023

Beyond Biotech podcast 40: Antibody-drug conjugates

This episode of the podcast is an in-depth look at antibody drug conjugates (ADCs). Our guests are Dr Pini Tsukerman, chief scientific of Nectin Therapeutics, and Matthew Robinson, chief technology…

March 31, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Mar 2023

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that…

March 14, 2023 - 6 minutesmins - By Jim Cornall

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering